Epacadostat
- Generic Name
- Epacadostat
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
- Conditions
- Recurrent/ Metastatic Endometrial Carcinoma
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT03310567
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Epacadostat and Pembrolizumab in Patients With GIST
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT03291054
- Locations
- 🇺🇸
U-M Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
- Conditions
- Advanced MalignanciesMetastatic Cancer
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 10
- Registration Number
- NCT03277352
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 129
- Registration Number
- NCT03260894
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03238638
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
- Conditions
- Advanced Solid TumorNon-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Chao Huang
- Target Recruit Count
- 15
- Registration Number
- NCT03217669
- Locations
- 🇺🇸
Clinical Research Center, Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Gastric CarcinomaStage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Unresectable Esophageal Carcinoma
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 3
- Registration Number
- NCT03196232
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- James J Lee
- Registration Number
- NCT03182894
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT03085914
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-10-08
- Target Recruit Count
- 41
- Registration Number
- NCT03006302
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.